Personalis transforms the active management of cancer through breakthrough personalized testing, aiming to drive a new paradigm for cancer management from biopsy through the life of the patient. The company provides highly sensitive assays that combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights for detecting minimal residual disease (MRD), recurrence, therapy selection, and drug development biomarker strategy.
